Table 4.
Cox-regression survival analysis.
| Chemotherapy regimen | Overall survival Adjusted modela |
Progression-free survival Adjusted model |
||||
|---|---|---|---|---|---|---|
| HRb | 95% CIc | P-value | HRb | 95%CIc | P-value | |
| ECF | 1 | - | 0.017 | 1 | - | 0.06 |
| DCF | 0.775 | 0.48-1,24 | 0.291 | 0.798 | 0.47-1.39 | 0.36 |
| FOLFOX | 0.677 | 0.39-1.15 | 0.151 | 0.810 | 0.588-1.812 | 0.45 |
| FLOT | 0.276 | 0.15-0.52 | 0.001 | 0.388 | 0.22-0.68 | 0.01 |
a Based on ECOG performance status, family history of cancer, disease histopathology, cancer stage, tumor size, and stage, having other organs’ metastasis, site of metastasis, resection rate, and response to chemotherapy; b hazard ratio; C confidence interval.